文献速递心力衰竭与心肌病冠心病

近期心肌梗死后慢性心衰疗法的应用评估与治疗开发:综述

Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
PubMed 文献 · JAMA Cardiol · 2022-01-01

本综述评估在近期心肌梗死(MI)后高风险患者中应用慢性心衰(HF)疗法的证据。射血分数降低的心衰(HFrEF)里程碑研究通常排除近期MI患者,而专门MI后试验显示部分疗法有获益,但沙库巴曲缬沙坦在慢性HF与MI后试验结果不一致,早期积极使用慢性HF有效疗法未能获益甚至有害。结论强调MI后人群与HFrEF人群存在差异,需专门试验。

要点

  • HFrEF里程碑研究通常排除近期MI患者,需专门MI后试验验证疗法。
  • 沙库巴曲缬沙坦在慢性HF与MI后试验结果不一致,提示疗效可能不同。
  • MI后早期积极使用慢性HF有效疗法未显示获益或与危害相关。

核心结论

  • MI后高风险HF患者与HFrEF人群存在差异,需专门试验评估疗法。

研究设计与样本

  • 综述总结HFrEF疗法在MI后高风险患者中的试验及新疗法探索。

主要发现

  • HFrEF里程碑研究通常排除近期MI患者,但专门MI后试验显示多种疗法有获益。
  • 沙库巴曲缬沙坦在慢性HF与MI后试验结果不一致。
  • MI后早期积极使用慢性HF有效疗法未能显示获益或与危害相关。

临床怎么用

  • MI后高风险患者应参考专门MI后试验证据,而非直接外推HFrEF疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Despite advances in cardiac care, patients remain at a high risk of death and the development of heart failure (HF) following myocardial infarction (MI). These risks are highest in patients with reduced ejection fraction (EF) or signs of HF immediately after MI. Drugs to mitigate these risks have been identified through the systematic evaluation of therapies with proven efficacy in patients with HF and reduced EF (HFrEF). OBSERVATIONS: Although landmark studies in patients with HFrEF consistently exclude patients with recent MI, dedicated post-MI trials of these drugs have led to multiple therapies with proven benefit in these patients. However, not all therapies with proven efficacy in patients with chronic HF have been shown to provide benefit in the post-MI population, as recently evidenced by the discrepant results between chronic HF and post-MI trials of sacubitril-valsartan. Similarly, multiple trials of early and aggressive use of therapies effective in chronic heart failure immediately post-MI failed to demonstrate benefit or were associated with harm, emphasizing the vulnerability of the post-MI population. CONCLUSIONS AND RELEVANCE: Trials of patients at high risk of HF following MI have emphasized the differences between the post-MI and HFrEF populations and the necessity for dedicated trials in the post-MI population. This review summarizes trials studying the use of these therapies for at-risk patients following MI from therapies used in patients with HFrEF and exploring new potential therapies for this high-risk population.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Harrington, Petrie, Anker, et al. Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. JAMA Cardiol. 2022. PMID: 36044233. doi:10.1001/jamacardio.2022.2847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。